Proteomics International Laboratories Ltd. · ASX:PIQ
Proteomics International Laboratories — Investor Presentation (February 2018)
22 slides from Proteomics International Laboratories's investor presentation, Feb 7, 2018
Slide 1: Alliance with CPR Pharma Services: Improving Drug Development
For personal use only Investor Presentation - Canary Capital | 8 February 2018 Alliance with CPR Pharma Services Improving Drug Development ASX: PIQ 1 Proteomics International Laboratories Ltd
Slide 2: Important Notice and Disclaimer
Important Notice and Disclaimer For personal use only These presentation materials and the accompanying verbal presentation (together, the Presentation Materials) are confidential and have been prepared by Proteomics International Laboratories Ltd (Company). By receiving the Presentation Materials,
Slide 3: Alliance overview
For personal use only Alliance overview 3 Proteomics International Laboratories Ltd
Slide 4: Alliance highlights: Summary
Alliance highlights: Summary For personal use only Proteomics International Laboratories Ltd (PIQ) is to collaborate with CPR Pharma Services (CPR) PIQ is a world leading specialist laboratory and diagnostics developer CPR is a regional leader in provision of clinical services and laboratory testing
Slide 5: Alliance highlights: Key benefits
Alliance highlights: Key benefits For personal use only The commodity: Diagnostic and Analytical tests for precision medicine The combined capabilities of Proteomics International Laboratories Ltd (PIQ) and CPR Pharma Services (CPR) are expected to create: $ Immediate cost benefits to streamline bus
Slide 6: Alliance: Strategic rationale
For personal use only Alliance: Strategic rationale 6 Proteomics International Laboratories Ltd
Slide 7: Strategic rationale: supply chain
Strategic rationale: supply chain For personal use only Proteomics International Specialist analytical laboratory for biologics Proven platform technology for developing new methods and novel diagnostic tests 7 Proteomics International Laboratories Ltd
Slide 8: Strategic rationale: supply chain completed
Strategic rationale: supply chain completed For personal use only CPR completes the circle High volume analytical laboratory for clinical trials Clinical services expanding into biosimilars Leveraging client relationships to drive new business in CDx 8 Proteomics International Laboratories Ltd
Slide 9: Strategic rationale: the Alliance
Strategic rationale: the Alliance For personal use only World class bioanalytics lab Expert in accredited analysis of biosimilars and biologics Specialist in method development for analytics and diagnostics Specialist, accredited pharmacokinetic (PK) testing for pre-clinical and clinical trials Glob
Slide 10: Value proposition: Synergies in combining PIQ diagnostics and CPR clinical trials
Value proposition: Synergies in combining PIQ diagnostics and CPR clinical trials For personal use only Australia is a global leader in clinical trials In 2016 there were over 1500 clinical trials run in Australia-NZ Efficient regulatory framework | High quality trial sites | Results accepted global
Slide 11: Recent sector transactions
Recent sector transactions For personal use only The sector is currently experiencing strong interest – all targets are Australian based Date Target Buyer Details Financials Aug 2017 Vivopharm Cancer Laboratory offering Acquisition Genetics preclinical phamacology, $15.3m toxicology & bioanalytics A
Slide 12: Strategic rationale: the details
For personal use only Strategic rationale: the details 12 Proteomics International Laboratories Ltd
Slide 13: Experienced board & management
Experienced board & management For personal use only Terry Sweet FAICD, Chairman Director of several listed companies over the past 30 years in both executive and non-executive capacities. Companies include XRF Scientific Ltd, where he was Managing Director for 4 years, Western Biotechnology Ltd, He
Slide 14: Overview: Proteomics International
Overview: Proteomics International For personal use only Specialist MedTech and Life Sciences company Revenue generating company – Est'd 2001 Listed on the Australian Stock Exchange April 2015 (code: PIQ) Global leader & innovator in field of proteomics World’s first company to receive ISO 17025 lab
Slide 15: Overview: CPR Pharma Services
Overview: CPR Pharma Services For personal use only Revenue generating (FY17: $15m) – Est'd 2009 Full service early phase (I and II) CRO FDA inspected with OECD GLP and ISO 17025 R&D laboratory accreditation Close relationship with Phase I clinical trial sites across Australia Serves a range of biot
Slide 16: Operating in fast growing markets
Operating in fast growing markets For personal use only Testing new protein drugs: biologics and biosimilars 7 of world's top 10 selling drugs are protein therapeutics (“biologics”) Fastest growing class of drug in development is biologics Manufacture of biosimilars is growing rapidly in Asia Biomar
Slide 17: Strategic rationale: Biosimilars testing
Strategic rationale: Biosimilars testing For personal use only Protein drugs, originally termed “biologics”, can perform highly complex functions that simple small chemicals cannot perform. Seven of the world's ten best selling drugs are protein-based drugs (“biologics”) Generic copies of these
Slide 18: Case study: Building a world leading predictive diagnostic test - PromarkerD
Case study: Building a world leading predictive diagnostic test - PromarkerD For personal use only Without PromarkerD With PromarkerD 18 Proteomics International Laboratories Ltd
Slide 19: Case study – the PromarkerD success story
Case study – the PromarkerD success story For personal use only The Problem 425 million people globally have diabetes (International Diabetes Foundation) 1 in 3 diabetic adults have chronic kidney disease (US Centre for Disease Control) There are no early symptoms of diabetic kidney disease There is
Slide 20: Clinical utility: both a diagnostic and companion diagnostic test
Clinical utility: both a diagnostic (Dx) and companion diagnostic (CDx) test For personal use only A new approach to managing diabetic kidney disease Product will launch in Q1 2018 Early detection, intervention, monitoring and management Identify at-risk individuals Tighter monitoring and control of
Slide 21: Please contact
Please contact For personal use only Richard Lipscombe Managing Director T: +61 8 9389 1992 | E: enquiries@proteomicsinternational.com www.proteomicsinternational.com Paul Hart Investor Relations, Canary Capital M:+61 421 051 474 | E: phart@canarycapital.com.au 21 Proteomics International Laboratori
Slide 22: For personal use only
For personal use only 22 Proteomics International Laboratories Ltd
Proteomics International Laboratories — Investor Presentation (February 2018) on 6ix